HIV-1 Reverse Transcriptase: A therapeutical target in the spotlight

被引:54
作者
Castro, HC
Loureiro, NIV
Pujol-Luz, M
Souza, AMT
Albuquerque, MG
Santos, DO
Cabral, LM
Frugulhetti, IC
Rodrigues, CR
机构
[1] Univ Fed Fluminense, Dept Biol Celular & Mol, IB, Lab Bioquim & Modelagem Mol LaBioMol, BR-24001970 Niteroi, RJ, Brazil
[2] Univ Fed Rio de Janeiro, Dept Quim Organ, IQ, Lab Modelagem Mol LabMMol, BR-21949900 Rio De Janeiro, Brazil
[3] Univ Fed Fluminense, Dept Biol Celular & Mol, IB, Mol Virol Lab, BR-24001970 Niteroi, RJ, Brazil
[4] Univ Fed Rio de Janeiro, Fac Farm, DLab Modelagem Mol & QSAR ModMolQSAR, BR-21941590 Rio De Janeiro, Brazil
关键词
reverse transcriptase; nucleoside; nucleotide; non-nucleoside; DNA; RNA; antiretroviral; AIDS;
D O I
10.2174/092986706775476089
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human Immunodeficiency Virus type 1 Reverse Transcriptase (HIV-1 RT) is one of the most important targets for treatment of Acquired Immune Deficiency Syndrome (AIDS). It catalyzes the reverse transcription of HIV-RNA into a double stranded DNA, and the knowledge of its substrate specificity and catalytic mechanism has guided the development of several inhibitors widely used on current HIV/AIDS therapy. However, mutations in HIV-1 RT structure can lead to the emergence of drug-resistant virus strains. The goal of this review is to summarize relevant structural features of HIV-1 RT and its inhibitors in such a way that this cost-effective target in the development of new antiretroviral drugs is particularly highlighted.
引用
收藏
页码:313 / 324
页数:12
相关论文
共 178 条
[41]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[42]  
De Clercq E, 2000, REV MED VIROL, V10, P255, DOI 10.1002/1099-1654(200007/08)10:4&lt
[43]  
255::AID-RMV282&gt
[44]  
3.0.CO
[45]  
2-6
[46]   Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection [J].
De Clercq, E .
FARMACO, 1999, 54 (1-2) :26-45
[47]   Antiviral drugs in current clinical use [J].
De Clercq, E .
JOURNAL OF CLINICAL VIROLOGY, 2004, 30 (02) :115-133
[48]   Strategies in the design of antiviral drugs [J].
De Clercq, E .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :13-25
[49]  
de Soultrait VR, 2003, CURR MED CHEM, V10, P1765
[50]   DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents [J].
de Soultrait, VR ;
Lozach, PY ;
Altmeyer, R ;
Tarrago-Litvak, L ;
Litvak, S ;
Andréola, ML .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 324 (02) :195-203